Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. — Stella

Recruiting

Back to Whole-Brain Radiotherapy trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing Municipality

Key details

Phase

Large-scale testing

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment target

~134 participants

Started

August 2025

Primary completion

August 2027

Age range

18 Years – 80 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov